FibroGen Inc (NASDAQ:FGEN) stock is sliding today, after the biotech company announced disappointing results from a late-stage trial of pamrevlumab, its experimental drug to treat patients with Duchenne muscular dystrophy. At last glance, FGEN was down 9% to trade at $17.02.
The stock's 80-day moving average kept a cap on gains the last couple sessions, and the stock is now back below the $18 level, which provided a firm line of pressure for most of May. Year-over-year, the equity is up about 65%.
It's also worth noting that short interest represents 6.2% of the stock's available float. It would take shorts over six days to cover their bets, at FGEN's average pace of trading.
Short-term options traders have been much more bearish than usual, per the stock's Schaeffer's put/call open interest ratio (SOIR) of 1.20, which sits in the 100th percentile of readings from the past 12 months.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report